Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, a precision medicine company, announced that its Chairman and CEO, Peter Maag, will present at the AAKP and George Washington University summit on July 16-17, 2020. The event focuses on innovations in kidney disease, particularly the role of artificial intelligence in transplant care. CareDx aims to enhance patient care through its digital tools, AiTraC and AlloCare, which address information management challenges for transplant patients. The summit highlights the global interest in improving transplant outcomes through data-driven solutions.
CareDx, Inc. (Nasdaq: CDNA) announced the publication of a study in Kidney360 evaluating its AlloSure tool against another monitoring method for kidney transplant rejection. The study, involving 76 patients, indicated that AlloSure provides faster results, with 75% of results delivered at least one day earlier than its counterpart, demonstrating superior accuracy in clinical interpretation. This validation highlights AlloSure's effectiveness in addressing transplant-specific testing needs.
CareDx (Nasdaq: CDNA) announced the full exercise of underwriters' option to purchase an additional 585,937 shares at $32.00 per share, resulting in net proceeds of approximately $17.6 million. This follows a public offering of 3,906,250 shares, which closed on June 15, 2020. With the additional shares, CareDx has sold a total of 4,492,187 shares, generating total net proceeds of around $134.7 million after expenses. The offering was managed by Goldman Sachs & Co. LLC and Jefferies LLC, among others.
CareDx, Inc. (Nasdaq: CDNA) has successfully closed a public offering of 3,906,250 shares of common stock priced at $32.00 per share, generating net proceeds of approximately $117.1 million. The underwriters also have a 30-day option to purchase an additional 585,937 shares. These funds are earmarked for working capital and general corporate purposes. The offering was conducted under a shelf registration statement, effective since June 9, 2020. Goldman Sachs & Co. LLC and Jefferies LLC served as joint book-running managers.
CareDx, Inc. (Nasdaq: CDNA) has announced the pricing of a public offering of 3,906,250 shares at $32.00 per share, aiming for gross proceeds of $125 million. The offering includes a 30-day option for underwriters to purchase an additional 585,937 shares. Expected to close around June 15, 2020, proceeds will support working capital and corporate purposes. The offering is registered under Form S-3ASR with the SEC. Goldman Sachs & Co. LLC and Jefferies LLC are leading the offering.
CareDx, Inc. (Nasdaq: CDNA) announced plans for an underwritten public offering of up to $100 million in its common stock. The company may grant underwriters a 30-day option to purchase an additional $15 million in shares. Proceeds will be used for working capital and general corporate purposes. The offering is contingent on market conditions and is being managed by Goldman Sachs & Co. LLC and Jefferies LLC. The offering is registered under a previously filed shelf registration statement with the SEC, and a preliminary prospectus will be available shortly.
CareDx, Inc. (Nasdaq: CDNA) announced an update regarding its 2020 Annual Meeting of Stockholders, which will now take place in a virtual format only due to COVID-19 restrictions. The meeting is scheduled for June 17, 2020, at 10:00 a.m. Pacific Time, and will cover the same agenda as previously communicated. Stockholders can still vote prior to the meeting using previously issued proxy materials. Instructions for attending the virtual meeting are provided, requiring a control number for stockholders, while guests can join with just their name and email.
CareDx, a precision medicine company focused on transplant patient solutions, announced its participation in the Goldman Sachs Global Healthcare Conference. The management will engage in a fireside chat on June 9, 2020, at 11:20 AM EDT. Interested stakeholders can access a live webcast through the company’s website. CareDx specializes in products and services that enhance the pre- and post-transplant experience, providing genomics-based information vital for transplant patients.
CareDx, Inc. (Nasdaq: CDNA) announced its participation in the Jefferies Virtual Healthcare Conference on June 3, 2020, at 11:00 AM EDT. The company, recognized for its precision medicine solutions for transplant patients, will provide a live webcast of its presentation available on its investor website. CareDx focuses on developing and commercializing high-value healthcare solutions and offers a range of products and services to support transplant patients and their caregivers.
CareDx, Inc. (Nasdaq: CDNA) has announced receiving CE mark approval for its AlloSeq Tx 17 technology, enhancing its availability for transplant patients, laboratories, and clinicians globally. This state-of-the-art solution offers superior donor organ matching and eliminates PCR disadvantages, improving workflow in Histocompatibility & Immunogenetics labs. Launched in September 2019, AlloSeq Tx 17 utilizes next-generation Hybrid Capture technology for HLA testing. CareDx aims to enhance patient care with genomics-based information, reinforcing its leadership in precision medicine for transplant solutions.
FAQ
What is the current stock price of CareDx (CDNA)?
What is the market cap of CareDx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
